---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-042508"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2026-09-14T13:29:43+00:00"
generated_at: "2026-09-14T13:31:07.726418+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# FDA approves Biofrontera's Ameluz PDT for superficial basal cell carcinoma; launch expected Q4 2026–Q1 2027

## Summary
- FDA approved sNDA for Ameluz (aminolevulinic acid) topical gel 10% + BF-RhodoLED lamp for sBCC in adults; first US PDT approved for skin cancer.
- Phase 3 trial (187 adults): composite complete response 66% (95/145) with Ameluz PDT vs 5% (2/42) placebo; histological clearance 76% vs 19%.
- Estimated US market: 540,000–720,000 sBCC cases/yr (approx. 15–20% of 3.6M BCC cases); existing AK indication retained.
- Commercial launch of sBCC indication planned late Q4 2026 through Q1 2027 using existing commercial organization and installed lamp base.
- CEO Hermann Luebbert calls approval a defining milestone; expands addressable market and strengthens PDT platform.

## SEC filing metadata
- accession: 0001493152-26-042508
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2026-09-14T13:29:43+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315226042508/0001493152-26-042508-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315226042508/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-042508
- JSON: https://secwatch.observer/filing/0001493152-26-042508.json
- Plain text: https://secwatch.observer/filing/0001493152-26-042508.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.